343 related articles for article (PubMed ID: 11350878)
1. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB; De Abreu RA; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
8. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
Uzunkoy A; Dilmec F; Ozgonul A; van Kuilenburg AB; Akkafa F
Anticancer Res; 2007; 27(6B):3899-902. PubMed ID: 18225548
[TBL] [Abstract][Full Text] [Related]
9. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
10. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
11. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function.
Van Kuilenburg AB; Meinsma R; Beke E; Bobba B; Boffi P; Enns GM; Witt DR; Dobritzsch D
Biol Chem; 2005 Apr; 386(4):319-24. PubMed ID: 15899693
[TBL] [Abstract][Full Text] [Related]
12. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
Coriat R; Chaussade S
Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
Magné N; Etienne-Grimaldi MC; Cals L; Renée N; Formento JL; Francoual M; Milano G
Br J Clin Pharmacol; 2007 Aug; 64(2):237-40. PubMed ID: 17335544
[TBL] [Abstract][Full Text] [Related]
14. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
15. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
[TBL] [Abstract][Full Text] [Related]
16. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
17. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
[TBL] [Abstract][Full Text] [Related]
18. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
Johnson MR; Wang K; Diasio RB
Clin Cancer Res; 2002 Mar; 8(3):768-74. PubMed ID: 11895907
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
Morel A; Boisdron-Celle M; Fey L; Lainé-Cessac P; Gamelin E
Clin Biochem; 2007 Jan; 40(1-2):11-7. PubMed ID: 17046731
[TBL] [Abstract][Full Text] [Related]
20. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
